Hypertension is a chronic clinical condition characterized by cardiovascular physiological impairment. It occurs when blood ...

(1) The total number of outstanding shares of the Company mentioned in the relevant transparency notification amounts to 63,145,080, each share giving right to one (1) vote (being 63,145,080 voting ...

Well, after the treatment for transthyretin cardiac amyloidosis has started, our main focus is to look at the progression of ...

Recurring nighttime disturbances, such as chest discomfort, itching, or frequent urination, may signal underlying health ...

Transparency Notification from Shareholder Ghent, Belgium - 10 October 2025 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of ...

The alfa pump® system received U.S. FDA Premarket Approval in December 2024 for the treatment of recurrent or refractory ascites due to liver cirrhosis. It is the first active implantable medical ...

Ghent, Belgium, 26 September 2025 - Sequana Medical NV(Euronext Brussels: SEQUA) (the "Company" or "SequanaMedical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, ...

Sequana Medical announces H1 2025 results and provides business update alfapump® US commercialisation underway; Strengthened US reimbursement with CMS approval of NTAP "top-up" reimbursement; On track ...

Sugary and artificially sweetened drinks raise the risk of metabolic liver disease Artificially sweetened drinks are also ...

This is an edition of The Wonder Reader, a newsletter in which our editors recommend a set of stories to spark your curiosity and fill you with delight. Sign up here to get it every Saturday morning.